INFORMAZIONE E APPROFONDIMENTO

Metastatic melanoma: Vemurafenib yielded an overall response rate of 56 percent and a median survival of nearly 16 months

Pubblicato: 16/10/2026

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.

Informazione, non una diagnosi.

Questi contenuti non sostituiscono una visita medica. Se noti un cambiamento o hai dubbi, rivolgiti al medico.